Blog

Regular posts covering guidance changes, inspection findings, data methodology, and Redica product updates.

Open filters
Search
Tags
Author
Alison Sathe
Anders Vinther
Barbara W. Unger
Jackie Torfin
Jerry Chapman
Jon Falker
Katie Terry
Mark Agostino
Rebecca Stauffer
Redica Systems
Roger Angarita
Sarah Boynton
Scott Sherrill
Subscribe to our Newsletter
Regular posts covering guidance changes, inspection findings, data methodology, and Redica product updates.

PRESS RELEASE – FDAzilla Announces New CEO

No items found.

The Heightened Importance of Contract Manufacturing Organizations

No items found.
Enforcement

FDA Sent These 11 Warning Letters for Pharma Companies | August 2017

No items found.

Summer Enforcement Actions for Compounding Pharmacies and Outsourcing Facilities

No items found.

US-EU Mutual Recognition Agreement of 2017

No items found.
Enforcement

FDA Sent These 6 Warning Letters for Pharma Companies | May 2017

No items found.

28 Unique Data Integrity Deficiencies That Aren’t Really Unique

No items found.

When Will the FDA Move On from Data Integrity?

No items found.

Warning Letters 2016 – Data Governance & Data Integrity

No items found.

Why is No One Talking About This? 2016 was the Year the FDA Exploded on China

No items found.

Delay, Denial, or Limiting of Inspections Since 2008

No items found.

Assessing Your Readiness State for FSMA: Stabilize, Then Benchmark

No items found.

The Story of 3 Consent Decrees

No items found.

EU vs. FDA: My Inspectors are More Rigorous Than Yours

No items found.

5 Features to Look for in an EIR

EIR
EIRs

To Understand Data Integrity, Just Read These 6 FDA 483s

No items found.

Welcome to the new FDAzilla.com

No items found.

5 FEATURES TO LOOK FOR IN A WARNING LETTER

No items found.